Divi's Laboratories Limited

DIVISLAB

INE361B01024

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 05:19:41 11/07/2025 pm IST			5-day change	1st Jan Change
6,835.00 ^INR	-0.14%		-1.04%	+12.07%

08/07	Divi's Laboratories Limited, Q4 2025 Earnings Call, May 17, 2025
08/07	INDIA STOCKS-India's stock benchmarks muted on tariff jitters; Trump says India deal close	RE

Jefferies Adjusts Divi's Laboratories' Price Target to INR6,200 From INR6,280, Keeps at Hold

Published on 19/05/2025 at 14:46

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Divi's Laboratories Limited

Divi's Laboratories Limited, Q4 2025 Earnings Call, May 17, 2025	08/07
INDIA STOCKS-India's stock benchmarks muted on tariff jitters; Trump says India deal close	08/07	RE
INDIA STOCKS-Indian shares advance on EU tariff relief, central bank's record dividend	26/05	RE
INDIA STOCKS-Indian benchmark indexes drop as US downgrade hits IT stocks; broader market up on rate cut hopes	19/05	RE
Jefferies Adjusts Divi's Laboratories' Price Target to INR6,200 From INR6,280, Keeps at Hold	19/05	MT
INDIA STOCKS-India's equity benchmarks flat as IT shares offset wider gains	19/05	RE
Divi's Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2025	17/05	CI
Divi's Laboratories Limited Announces Executive Changes, Effective August 01, 2025	17/05	CI
Divi's Laboratories Limited Announces Chief Financial Officer Changes, Effective August 01, 2025	17/05	CI
Indian pharma stocks fall as Trump moves to cut U.S. drug prices	12/05	RE
INDIA STOCKS-Indian equity benchmarks snap winning run on risk-off after Kashmir attack	24/04	RE
Trump Skipping Pharma Tariffs Bouys Sector Stocks in India	03/04	DJ
INDIA STOCKS-Indian shares buck global trade war fears to log best day in a month	04/02	RE
Divi's Laboratories Posts Gains in Fiscal Q3 Consolidated Profit	04/02	MT
INDIA STOCKS-Indian shares breathe a sigh of relief on US tariffs pause	04/02	RE
INDIA STOCKS-Indian shares tumble as trade war shockwaves reach Mumbai	03/02	RE
Divi's Laboratories Limited, Q3 2025 Earnings Call, Feb 03, 2025	03/02
India's Divi's Labs beats Q3 profit estimates on strong API demand; shares rise	03/02	RE
India's Divi's Labs beats Q3 profit estimates on strong API demand; shares rise	03/02	RE
Divi's Laboratories Limited Appoints Manoranjan Jasti as Chief Information Officer	03/02	CI
Divi's Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	03/02	CI
Divi's Laboratories Limited Announces Commencement of Commercial Operations at Unit III Greenfield Project at Kakinada, Andhra Pradesh in Phased Managed	02/01	CI
Jefferies Adjusts Divi's Laboratories' Price Target to INR5,790 From INR4,830, Keeps at Hold	11/11	MT
Divi's Laboratories Posts Gains in Fiscal Q2 Consolidated Profit	11/11	MT
Divi's Laboratories Limited, Q2 2025 Earnings Call, Nov 09, 2024	09/11

Chart Divi's Laboratories Limited

Duration

Period

DIVISLAB: Dynamic Chart

Divi's Laboratories Limited is specialized in the development and manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Net sales by source of revenue break down into product sales (97.9%) and service sales (2.1%). At the end of March 2020, the group has 2 production sites located in India.

Employees

9,741

Sector

Pharmaceuticals

Calendar

25/07 - Détachement de for final dividend

More about the company